Skip to content
Screener

PTC Therapeutics PTCT Shares (Diluted)

Shares (Diluted) at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
105.4M-1.1%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
194.5M-1.3%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
57.4M+25.9%
ALN
Alnylam PharmaceuticalsALNY
138.3M+5.9%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
107.1M+12.6%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
47.2M+6.5%

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.78B+41.9%
Enterprise value$5.34B+54.9%
P/E7.1×
P/S+4.7×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001070081-26-000012
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
(Loss) income before income tax expense(2,462)929,828
Income tax expense(347)(63,266)
Net (loss) income attributable to common stockholders$(2,809)$866,562
Weighted-average shares outstanding:
Basic (in shares)82,521,02378,115,836
Diluted (in shares)82,521,02386,385,922
Net (loss) income per share—basic (in dollars per share)$(0.03)$11.09
Net (loss) income per share—diluted (in dollars per share)$(0.03)$10.04

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's shares (diluted)?
PTC Therapeutics (PTCT) reported shares (diluted) of 82.5M in Q1 2026.
How has PTC Therapeutics's shares (diluted) changed year-over-year?
PTC Therapeutics's shares (diluted) decreased by 4.5% year-over-year, from 86.4M to 82.5M.
What is the long-term trend for PTC Therapeutics's shares (diluted)?
Over 4 years (2021 to 2025), PTC Therapeutics's shares (diluted) has grown at a 4.8% compound annual growth rate (CAGR), from 281.7M to 340M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about PTC Therapeutics's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude